The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model

Investigative Ophthalmology and Visual Science

Volumn 42, Issue 8, 2001, Pages 1812-1815

  Romanowski, E G ^a   Gordon, Y J ^a   Araullo Cruz, T ^a   Yates, K A ^a   Kinchington, P R ^a  

^a University of Pittsburgh School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; SODIUM CHLORIDE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; INOCULATION; NEW ZEALAND; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; RABBIT; VIRUS CULTURE; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ANIMALS; ANTIVIRAL AGENTS; CONJUNCTIVITIS, VIRAL; CYTOSINE; DRUG RESISTANCE, MICROBIAL; FEMALE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RABBITS; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 0034933241     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Adenovirus keratoconjunctivitis
2. Therapeutic potential of HPMPC as an antiviral
3. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model
4. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model
5. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model
6. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis
7. HPMPC, a broad-spectrum topical antiviral, inhibits HSV-1 replication and promotes healing of dendritic keratitis in the NZ rabbit ocular model
8. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis
9. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model
10. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir
11. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus
12. Molecular basis for the development of resistance to the new broad spectrum antiviral cidofovir in human adenovirus type 5
13. Recovery of adenovirus type 5 recombinants resistant to cidofovir
14. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture
15. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer gancyclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS
16. Cytomegalovirus drug resistance
17. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis
18. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene
19. Resistance of human cytomegalovirus to antiviral drugs
20. Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both gancyclovir and cidofovir
21. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease
22. Cidofovir
23. Cytomegalovirus retinitis and viral resistance: Gancyclovir resistance
24. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance
25. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro